Levetiracetam Versus Sodium Valproate in Children: Evidence Review

What was studied

This systematic review and meta-analysis compared levetiracetam with sodium valproate in children age 18 or younger with new-onset epilepsy or established status epilepticus. Eight studies were included: seven randomized controlled trials and one prospective cohort study. The abstract does not report the total number of children.

Researchers combined study results to compare seizure freedom and adverse effects. They also rated the certainty of the evidence.

What they found

The two medicines had similar seizure-control results. For seizure freedom, the pooled result was RR 1.01 (95% CI 0.93–1.10), indicating no clear difference. There was also no clear difference in failure to achieve seizure freedom.

Levetiracetam was associated with fewer overall adverse effects than sodium valproate (RR 0.78, 95% CI 0.68–0.89) and less weight gain (RR 0.22, 95% CI 0.10–0.46). Evidence for these two findings was rated high certainty. No statistically significant differences were found for behavioral changes or skin rash. The confidence interval for behavioral changes was wide, indicating uncertainty about the relative risk.

Limits of the evidence

The abstract does not provide the total number of participants, treatment doses, follow-up duration, epilepsy subtypes, ages within the pediatric range, or detailed study-quality findings. The analysis included children from two different clinical contexts—new-onset epilepsy and established status epilepticus—and the abstract does not report separate results for these groups. One included study was a prospective cohort rather than a randomized trial. The wide confidence interval for behavioral changes means a clinically important difference cannot be ruled out. Longer follow-up is needed to confirm long-term efficacy. Reproductive safety and medicine-interaction risk were mentioned in the conclusion but were not reported as pooled outcomes in the abstract.

For families and caregivers

These findings suggest that levetiracetam and sodium valproate provide similar seizure control overall in the studied children, while levetiracetam is associated with fewer overall adverse effects and less weight gain. Treatment choice may depend on the child’s clinical situation and the side effects of greatest concern. Behavioral symptoms should still be monitored because the available evidence did not establish a clear difference between the medicines in this area.

What to watch next

Longer, high-quality pediatric trials are needed to confirm long-term efficacy.

Terms in this summary

status epilepticus

A prolonged seizure or repeated seizures without adequate recovery between them; it is a medical emergency.

monotherapy

Treatment using one antiseizure medicine rather than a combination.

meta-analysis

A method that combines numerical results from several studies.

risk ratio (RR)

A comparison of how often an outcome occurred in one treatment group versus another; an RR of 1 suggests no difference.

95% confidence interval (CI)

A range showing the uncertainty around an estimated result. If the interval for a risk ratio includes 1, a clear difference has not been shown.

adverse effects

Unwanted or harmful effects that occur during treatment.

high-certainty evidence

Evidence rated as unlikely to change greatly with additional research, although it is not a guarantee.